Facebook Instagram Twitter RSS Feed PodBean Back to top on side

Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma

In: NEOPLASMA, vol. 57, no. 2
G Radosavljevic - B Ljujic - I Jovanovic - Z Srzentic - S Pavlovic - N Zdravkovic - M Milovanovic - D Bankovic - M Knezevic - L Acimovic - N Arsenijevic
Detaily:
Rok, strany: 2010, 135 - 144
O článku:
The promotion of tumor growth is due to a combination of several mechanisms, including angiogenesis and the abundance of cell-derived inflammatory cytokines. The aim of this study was to investigate the serum levels of interleukin 17 (IL-17) and the expression of p53 and Vascular Endothelial Growth Factor (VEGF), in order to determine the relationship between these markers and serum IL-17 levels in patients with colorectal carcinoma. <br />Serum levels of the proinflammatory cytokine IL-17 in patients with colorectal carcinoma (CRC) (n=40) and in a healthy group (n=37) were analysed by ELISA. Surgically resected specimens of 59 colorectal carcinomas were studied by immunohistochemical staining for VEGF and p53. <br />Analyses by ELISA showed significantly higher IL-17 serum levels in patients with colorectal carcinoma than in control subjects (IL-17; mean 128.52±47.62 pg/ml vs. mean 101.91±22.46 pg/ml; p=0.022). We also found an inverse correlation between p53 expression and the level of IL-17 in the serum of patients with CRC. In fact, the serum concentration of IL-17 was significantly higher in patients who did not express p53 (p=0.023). There was no significant correlation between the expression of p53 and VEGF. However, concomitant expression of VEGF and p53 showed a significant correlation with the histological and nuclear grade of the carcinoma.<br />The data presented in our study indicate that IL-17 might act as a valuable tumor marker in patients with CRC and that combined analysis of p53 and VEGF expression might provide additional information about tumor features. Keywords: colorectal carcinoma (CRC),interleukin-17 (IL-17), p53, vascular endothelial growth factor (VEGF)
Ako citovať:
ISO 690:
Radosavljevic, G., Ljujic, B., Jovanovic, I., Srzentic, Z., Pavlovic, S., Zdravkovic, N., Milovanovic, M., Bankovic, D., Knezevic, M., Acimovic, L., Arsenijevic, N. 2010. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. In NEOPLASMA, vol. 57, no.2, pp. 135-144. 0028-2685.

APA:
Radosavljevic, G., Ljujic, B., Jovanovic, I., Srzentic, Z., Pavlovic, S., Zdravkovic, N., Milovanovic, M., Bankovic, D., Knezevic, M., Acimovic, L., Arsenijevic, N. (2010). Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. NEOPLASMA, 57(2), 135-144. 0028-2685.